HUE060282T2 - Béta-laktamáz gátló vegyületek - Google Patents
Béta-laktamáz gátló vegyületekInfo
- Publication number
- HUE060282T2 HUE060282T2 HUE17784063A HUE17784063A HUE060282T2 HU E060282 T2 HUE060282 T2 HU E060282T2 HU E17784063 A HUE17784063 A HU E17784063A HU E17784063 A HUE17784063 A HU E17784063A HU E060282 T2 HUE060282 T2 HU E060282T2
- Authority
- HU
- Hungary
- Prior art keywords
- beta
- inhibitor compounds
- lactamase inhibitor
- lactamase
- compounds
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0892—Compounds with a Si-O-N linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395464P | 2016-09-16 | 2016-09-16 | |
| US201762456423P | 2017-02-08 | 2017-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE060282T2 true HUE060282T2 (hu) | 2023-02-28 |
Family
ID=60083416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17784063A HUE060282T2 (hu) | 2016-09-16 | 2017-09-15 | Béta-laktamáz gátló vegyületek |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10800778B2 (hu) |
| EP (1) | EP3512851B1 (hu) |
| JP (2) | JP6997178B2 (hu) |
| KR (1) | KR102537340B1 (hu) |
| CN (2) | CN114591223A (hu) |
| AU (1) | AU2017325863B2 (hu) |
| BR (1) | BR112019005053A2 (hu) |
| CA (1) | CA3036557A1 (hu) |
| DK (1) | DK3512851T3 (hu) |
| ES (1) | ES2927986T3 (hu) |
| HR (1) | HRP20221217T1 (hu) |
| HU (1) | HUE060282T2 (hu) |
| IL (2) | IL289686B2 (hu) |
| LT (1) | LT3512851T (hu) |
| MA (1) | MA46242A (hu) |
| MX (2) | MX2019003060A (hu) |
| PH (1) | PH12019500558A1 (hu) |
| PL (1) | PL3512851T3 (hu) |
| PT (1) | PT3512851T (hu) |
| SG (1) | SG11201901658PA (hu) |
| SI (1) | SI3512851T1 (hu) |
| TW (1) | TWI773687B (hu) |
| WO (1) | WO2018053215A1 (hu) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114591223A (zh) * | 2016-09-16 | 2022-06-07 | 恩塔西斯治疗有限公司 | β-内酰胺酶抑制剂化合物 |
| TWI791018B (zh) | 2017-05-08 | 2023-02-01 | 美商安特西醫療公司 | 治療細菌感染之化合物及方法 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN112209928B (zh) * | 2019-07-10 | 2023-02-17 | 华东理工大学 | 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用 |
| CN110898999A (zh) * | 2019-11-26 | 2020-03-24 | 中国矿业大学 | 一种煤焦油基煤泥浮选药剂及其制备方法 |
| CN111790439B (zh) * | 2020-07-29 | 2022-12-27 | 成都能特科技发展有限公司 | 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用 |
| JP2024512793A (ja) * | 2021-04-05 | 2024-03-19 | キューペックス バイオファーマ， インコーポレイテッド | セフチブテン投与レジメン |
| US11814385B2 (en) * | 2021-06-25 | 2023-11-14 | University Of South Florida | Small molecule inhibitors targeting Clostridioides difficile sporulation |
| WO2023206580A1 (en) | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
| US20230398101A1 (en) * | 2022-06-09 | 2023-12-14 | Fleurir Abx Llc | Co-agents as Therapy Against Anaerobic Pathogens |
| CN116693531A (zh) * | 2023-06-09 | 2023-09-05 | 河南师范大学 | 一种桥联多环内酰胺类化合物的合成方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607041A (en) * | 1983-04-27 | 1986-08-19 | Fisons Plc | Antihypertensive 2-phenyl Hantzsch dihydropyridines |
| PL179435B1 (pl) | 1993-12-29 | 2000-09-29 | Pfizer | Diazabicykliczni antagonisci neurokininy PL |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| UA101966C2 (en) | 2008-01-18 | 2013-05-27 | Мерк Шарп Енд Доме Корп. | Beta-lactamase inhibitors |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| DK2562155T3 (da) * | 2010-04-20 | 2019-06-24 | Fujifilm Toyama Chemical Co Ltd | Hydroxaminsyrederivat |
| EP2768503A1 (en) | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| CN103687598B (zh) | 2011-07-26 | 2016-03-16 | 沃克哈特有限公司 | 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物 |
| JP5666743B2 (ja) * | 2011-08-27 | 2015-02-12 | ウォックハート リミテッド | １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用 |
| WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
| AU2012310136B2 (en) | 2011-09-13 | 2016-07-07 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| KR20150003777A (ko) | 2012-03-30 | 2015-01-09 | 큐비스트 파마슈티컬즈 인코포레이티드 | 이속사졸 β-락타마제 억제제 |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| MX366948B (es) | 2012-05-30 | 2019-07-30 | Meiji Seika Pharma Co Ltd | Nuevo inhibidor de beta-lactamasa y proceso para prepararlo. |
| CA2881169C (en) | 2012-08-25 | 2020-06-16 | Wockhardt Limited | 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections |
| WO2014033561A1 (en) | 2012-09-03 | 2014-03-06 | Wockhardt Limited | Antibacterial compositions |
| WO2014122468A1 (en) | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| RS58429B1 (sr) | 2014-11-17 | 2019-04-30 | Entasis Therapeutics Ltd | Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija |
| RU2017133660A (ru) * | 2015-03-31 | 2019-03-28 | Мутабилис | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций |
| CN114591223A (zh) * | 2016-09-16 | 2022-06-07 | 恩塔西斯治疗有限公司 | β-内酰胺酶抑制剂化合物 |
| KR20230007830A (ko) * | 2021-07-06 | 2023-01-13 | 현대자동차주식회사 | 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체 |
-
2017
- 2017-09-15 CN CN202210161577.5A patent/CN114591223A/zh active Pending
- 2017-09-15 PL PL17784063.4T patent/PL3512851T3/pl unknown
- 2017-09-15 MA MA046242A patent/MA46242A/fr unknown
- 2017-09-15 KR KR1020197010376A patent/KR102537340B1/ko active IP Right Grant
- 2017-09-15 BR BR112019005053A patent/BR112019005053A2/pt unknown
- 2017-09-15 CA CA3036557A patent/CA3036557A1/en active Pending
- 2017-09-15 AU AU2017325863A patent/AU2017325863B2/en active Active
- 2017-09-15 MX MX2019003060A patent/MX2019003060A/es unknown
- 2017-09-15 DK DK17784063.4T patent/DK3512851T3/da active
- 2017-09-15 WO PCT/US2017/051692 patent/WO2018053215A1/en unknown
- 2017-09-15 TW TW106131860A patent/TWI773687B/zh active
- 2017-09-15 LT LTEPPCT/US2017/051692T patent/LT3512851T/lt unknown
- 2017-09-15 US US16/333,900 patent/US10800778B2/en active Active
- 2017-09-15 JP JP2019515241A patent/JP6997178B2/ja active Active
- 2017-09-15 EP EP17784063.4A patent/EP3512851B1/en active Active
- 2017-09-15 SI SI201731232T patent/SI3512851T1/sl unknown
- 2017-09-15 MX MX2021010077A patent/MX2021010077A/es unknown
- 2017-09-15 ES ES17784063T patent/ES2927986T3/es active Active
- 2017-09-15 PT PT177840634T patent/PT3512851T/pt unknown
- 2017-09-15 CN CN201780057302.4A patent/CN109715630B/zh active Active
- 2017-09-15 HR HRP20221217TT patent/HRP20221217T1/hr unknown
- 2017-09-15 HU HUE17784063A patent/HUE060282T2/hu unknown
- 2017-09-15 IL IL289686A patent/IL289686B2/en unknown
- 2017-09-15 SG SG11201901658PA patent/SG11201901658PA/en unknown
-
2019
- 2019-03-11 IL IL265276A patent/IL265276B/en unknown
- 2019-03-15 PH PH12019500558A patent/PH12019500558A1/en unknown
-
2021
- 2021-12-16 JP JP2021203942A patent/JP7281527B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257880B (en) | Beta-lactamase inhibitors | |
| IL289686A (en) | Beta-lactamase inhibitor compounds | |
| IL281537A (en) | EGFR inhibitor compounds | |
| EP3347008A4 (en) | BETA-Lactamase INHIBITORS | |
| GB201705971D0 (en) | Inhibitor compounds | |
| GB201403536D0 (en) | Inhibitor compounds | |
| GB201513481D0 (en) | Inhibitor compounds | |
| GB201505658D0 (en) | Inhibitor compounds | |
| IL275532B1 (en) | mtor inhibitory compounds | |
| GB201612860D0 (en) | Inhibitors | |
| EP3466950A4 (en) | NOVEL BETA LACTAMASE INHIBITORS | |
| IL275531B1 (en) | mtor inhibitory compounds | |
| IL265626B (en) | beta-lactamase inhibitors | |
| ZA201805158B (en) | Carbapenem compounds | |
| PT3420078T (pt) | Variantes da beta-lactamase | |
| GB201621619D0 (en) | Inhibitor compounds | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201522453D0 (en) | Inhibitor compounds | |
| GB201500644D0 (en) | Inhibitor compounds | |
| GB201401792D0 (en) | Beta-lactam compounds |